The electronic measurement instrument research and manufacturing company, Dikaosi Instrument (301689.SZ), plans to publicly issue 102 million shares.
Electric Science Co., Ltd. (301689.SZ) disclosed its prospectus, indicating that the company plans to publicly issue 102 million shares, accounting for 11% of the total share capital after this issuance. The initial number of shares for strategic placement in this issuance is 40.8278 million shares, representing 40% of the total issuance. The preliminary inquiry date for this issuance is set for August 25, 2026, and the subscription date is August 28, 2026.
Electric Science Instrument (301689.SZ) has disclosed its prospectus, indicating that the company plans to publicly issue 102 million shares, which represents 11% of the total share capital post-issuance. The initial strategic placement for this issuance amounts to 40.8278 million shares, accounting for 40% of the total issued shares. The preliminary inquiry date for this public offering is set for August 25, 2026, with the subscription date on August 28, 2026.
The company is a high-tech enterprise specializing in the research and development, manufacturing, and sales of electronic measurement instruments. It is the most comprehensive company in Chinas electronic measurement instrument industry, with the widest range of products and spectrum coverage. Key products include complete machines, testing systems, and complete components. Backed by decades of deep technical accumulation, the company has cultivated the largest team of research talents in China, equipped with top-tier R&D conditions and industrialization capabilities. It is the strongest and largest electronic measurement instrument R&D and manufacturing enterprise in terms of overall strength and revenue scale in China. Moreover, it is currently the only electronic measurement instrument company in China that can fully benchmark against internationally leading enterprises in microwave/mm-wave, optoelectronics, communications, and basic measurement instrument sectors. The overall technical level is domestically leading, especially in the microwave/mm-wave measurement instrument field, which has reached an internationally advanced level, with certain subfields achieving international leadership.
The company's net profits attributable to the parent company for the years 2023 to 2025 are projected to be 190 million yuan, 275 million yuan, and 438 million yuan, respectively. From January to September 2026, the company expects to achieve operating revenues between 1.52 billion and 1.68 billion yuan, reflecting a change of approximately -5.00% to 5.00% compared to the same period last year; net profits are expected to be between 245 million and 265 million yuan, with a change of approximately -2.05% to 5.95% year-on-year; and the net profit after deducting non-recurring gains and losses is expected to range from 225 million to 245 million yuan, showing a change of approximately -2.77% to 5.87% compared to last years same period. The overall operational situation of the company from January to September 2026 is stable, with no significant changes in the main performance data compared to the same period last year.
The funds raised from this issuance, after deducting issuance expenses, are planned to be invested in: upgrading and expanding production lines for high-end electronic measurement instruments, R&D and industrialization construction projects for next-generation mobile communication testing, construction of a technology innovation center, and replenishing working capital, with a total intended investment amounting to 1.5 billion yuan.
Related Articles

Tcl Corporation (000100.SZ) has received approval from the China Securities Regulatory Commission for its share issuance and acquisition.

HIGH FASHION (00608) issues a profit warning, expecting that interim profits will decrease by approximately 45% to 65% compared to the same period last year.

LEADS BIOLABS-B(09887): The summary of the Phase II clinical study of Vilex (Opalimab, a PD-L1/4-1BB bispecific antibody, LBL-024) as a first-line treatment for NSCLC has been published on the WCLC website.
Tcl Corporation (000100.SZ) has received approval from the China Securities Regulatory Commission for its share issuance and acquisition.

HIGH FASHION (00608) issues a profit warning, expecting that interim profits will decrease by approximately 45% to 65% compared to the same period last year.

LEADS BIOLABS-B(09887): The summary of the Phase II clinical study of Vilex (Opalimab, a PD-L1/4-1BB bispecific antibody, LBL-024) as a first-line treatment for NSCLC has been published on the WCLC website.

RECOMMEND





